MA46750A - Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents - Google Patents

Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents

Info

Publication number
MA46750A
MA46750A MA046750A MA46750A MA46750A MA 46750 A MA46750 A MA 46750A MA 046750 A MA046750 A MA 046750A MA 46750 A MA46750 A MA 46750A MA 46750 A MA46750 A MA 46750A
Authority
MA
Morocco
Prior art keywords
ralinepag
agents
combinations
methods
treating pah
Prior art date
Application number
MA046750A
Other languages
English (en)
Inventor
John W Adams
Dominic P Behan
Lucie H Clapp
Original Assignee
Arena Pharm Inc
Lucie H Clapp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc, Lucie H Clapp filed Critical Arena Pharm Inc
Publication of MA46750A publication Critical patent/MA46750A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA046750A 2016-11-10 2017-11-10 Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents MA46750A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662420515P 2016-11-10 2016-11-10
US201762530533P 2017-07-10 2017-07-10

Publications (1)

Publication Number Publication Date
MA46750A true MA46750A (fr) 2019-09-18

Family

ID=60451197

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046750A MA46750A (fr) 2016-11-10 2017-11-10 Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents

Country Status (11)

Country Link
US (2) US12377067B2 (fr)
EP (2) EP4681708A3 (fr)
JP (3) JP2019533713A (fr)
KR (4) KR20230021186A (fr)
CN (2) CN119367341A (fr)
AU (3) AU2017357759A1 (fr)
CA (1) CA3043283A1 (fr)
ES (1) ES3052035T3 (fr)
IL (2) IL266518B2 (fr)
MA (1) MA46750A (fr)
WO (1) WO2018089804A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230021186A (ko) 2016-11-10 2023-02-13 아레나 파마슈티칼스, 인크. 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법
EP3977985B1 (fr) 2017-03-01 2023-09-06 Arena Pharmaceuticals, Inc. Compositions comprenant des agonistes du récepteur pgi2 et procédés de préparation associés
KR20210040837A (ko) * 2018-05-16 2021-04-14 아레나 파마슈티칼스, 인크. Pgi2-수용체 효능제를 포함하는 조성물 및 그의 제조 방법
CN108721296B (zh) * 2018-07-03 2019-04-05 中国人民解放军总医院 一种化合物在治疗或预防高原病中的用途
CN112638865B (zh) * 2018-09-06 2022-07-26 广东东阳光药业有限公司 药物共晶体及其制备方法
SMT202400274T1 (it) * 2018-12-21 2024-09-16 Actelion Pharmaceuticals Ltd Macitentan per il trattamento di ipertensione arteriosa polmonare
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
US20230263807A1 (en) * 2022-02-08 2023-08-24 United Therapeutics Corporation Treprostinil iloprost combination therapy
WO2023158634A1 (fr) 2022-02-15 2023-08-24 United Therapeutics Corporation Agoniste du récepteur de prostacycline (ip) cristalline et ses utilisations
US20250282716A1 (en) 2024-03-11 2025-09-11 United Therapeutics Corporation Methods of making ip-receptor agonists
CN121714543A (zh) * 2024-09-23 2026-03-24 上海欣药智能科技有限公司 一种可吸入的含可溶性鸟苷酸环化酶受体激动剂的药物组合物及其用途
US12582629B1 (en) * 2025-10-23 2026-03-24 Innovate Therapeutics Llc Extended-release pharmaceutical compositions of Ralinepag

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085844A1 (fr) 1991-12-27 1993-06-28 Nobuyuki Hamanaka Derives fusionnes de l'acide benzeneoxyacetique
GB9908934D0 (en) 1999-04-19 1999-06-16 Rolic Ag Liquid crystalline compounds
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
WO2002055484A1 (fr) 2001-01-12 2002-07-18 Takeda Chemical Industries, Ltd. Compose biaryle, procede de production de ce compose, et principe actif
AU2002322585A1 (en) 2001-07-20 2003-03-03 Adipogenix, Inc. Fat accumulation-modulating compounds
NZ531153A (en) 2001-08-09 2005-10-28 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TWI293715B (en) 2002-10-10 2008-02-21 Sipix Imaging Inc A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display
EP1603878B1 (fr) 2003-02-10 2013-01-02 Vertex Pharmaceuticals Incorporated Procedes de preparation de n-heteroaryl-n-aryl-amines par mise en reaction d'un ester d'acide n-aryl-carbamique avec un halo-heteroaryle, et procedess analogues
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
JP2008510726A (ja) 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
WO2007051255A1 (fr) 2005-11-04 2007-05-10 The University Of Sydney Procédé de synthèse de composés contenant un système azacyclique
AU2007249827A1 (en) 2006-05-09 2007-11-22 Colorado State University Research Foundation Methods for treating blood disorders
CN110003123B (zh) 2008-03-18 2023-06-23 艾尼纳制药公司 用于治疗前列环素(pgi2)受体相关病症的pgi2受体调节剂
AU2009325117C1 (en) 2008-11-26 2014-12-18 Arena Pharmaceuticals, Inc. Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
EP2370413B1 (fr) 2008-12-08 2015-08-05 Arena Pharmaceuticals, Inc. Modulateurs du récepteur de prostacycline (pgi2) utiles pour le traitement de troubles associés à celui-ci
WO2011037613A1 (fr) * 2009-09-23 2011-03-31 Arena Pharmaceuticals, Inc. Formes cristallines et procédés pour la préparation d'agonistes du récepteur pgi2
WO2013040068A2 (fr) 2011-09-12 2013-03-21 Irix Pharmaceuticals, Inc. Procédé de préparation de prostacyclines synthétiques
JP6357481B2 (ja) * 2012-11-30 2018-07-11 インスメッド， インコーポレイテッド プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法
MX394186B (es) * 2014-10-23 2025-03-24 Arena Pharm Inc Metodo de tratamiento de afecciones relacionadas con el receptor pgi2
KR102569428B1 (ko) * 2015-01-13 2023-08-21 비버스 인크. 폐 고혈압을 위한 병용 요법
KR20230021186A (ko) 2016-11-10 2023-02-13 아레나 파마슈티칼스, 인크. 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법

Also Published As

Publication number Publication date
KR20200015439A (ko) 2020-02-12
AU2023263497B2 (en) 2025-09-18
EP4681708A2 (fr) 2026-01-21
KR20260020212A (ko) 2026-02-10
WO2018089804A1 (fr) 2018-05-17
WO2018089804A9 (fr) 2018-06-21
KR102916884B1 (ko) 2026-01-22
JP2019533713A (ja) 2019-11-21
AU2025283444A1 (en) 2026-01-15
IL266518B1 (en) 2026-01-01
ES3052035T3 (en) 2025-12-30
AU2023263497A1 (en) 2023-11-30
IL323354A (en) 2025-11-01
US20260014114A1 (en) 2026-01-15
CN110691612A (zh) 2020-01-14
CA3043283A1 (fr) 2018-05-17
CN110691612B (zh) 2024-11-08
US12377067B2 (en) 2025-08-05
IL266518A (en) 2019-07-31
JP2023029865A (ja) 2023-03-07
AU2023263497C1 (en) 2026-01-22
KR20240068077A (ko) 2024-05-17
IL266518B2 (en) 2026-05-01
EP3538154B1 (fr) 2025-09-03
JP2025131627A (ja) 2025-09-09
KR20230021186A (ko) 2023-02-13
AU2017357759A1 (en) 2019-06-06
CN119367341A (zh) 2025-01-28
EP3538154A1 (fr) 2019-09-18
EP4681708A3 (fr) 2026-03-18
US20190321328A1 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
EP3668500A4 (fr) Méthodes de traitement de l'arthrose à l'aide d'un gel de cannabidiol transdermique
EP3226848A4 (fr) Méthodes de traitement de l'alopécie en aires à l'aide d'approches de modulation génique
EP3471780A4 (fr) Traitement de la dmla à l'aide d'un variant d'aav2 et d'aflibercept
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA40867A (fr) Méthodes pour le traitement d'infections virales à filoviridae
EP3436052A4 (fr) Traitement d'une faiblesse musculaire à l'aide de phosphatases alcalines
EP3436020A4 (fr) Méthodes de traitement de l'hypophosphatasie chez les adolescents et les adultes
EP3607072A4 (fr) Compositions et méthodes de traitement de la phénylcétonurie
EP3340971A4 (fr) Méthodes de traitement de syndrome de lennox-gastaut à l'aide de fenfluramine
MA42450A (fr) Méthodes de traitement de la stéatose hépatique non alcoolique et/ou de la lipodystrophie
EP3426286A4 (fr) Méthodes de traitement de l'hypophosphatasie chez l'enfant
EP3512524A4 (fr) Méthodes et compositions de traitement d'infections virales
EP3423100A4 (fr) Compositions destinées à traiter l'inflammation et méthodes de traitement associées
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
EP3432891A4 (fr) Méthodes de traitement et de prévention d'une infection à c. difficile
EP3519058C0 (fr) Compositions et méthodes de traitement des cheveux
EP3405191A4 (fr) Méthodes et compositions pour le traitement de l'hyperhidrose
EP3426777A4 (fr) Vecteurs de combinaison et méthodes de traitement du cancer
EP3458079A4 (fr) Compositions et méthodes pour le traitement de l'acné
EP3503904A4 (fr) Traitement par ascaroside de l'oesophagite à éosinophiles
MA46967A (fr) Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
MA41120A (fr) Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
MA43230A (fr) Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
EP3400008A4 (fr) Compositions thérapeutiques et méthodes pour le traitement de l'hépatite b
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose